{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:14:18Z","timestamp":1793830458160,"version":"4.6.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Markedly expressed on hematopoietic stem cells, C-X-C motif chemokine receptor 4 (CXCR4)-directed radioligand therapy (RLT) has been used in relapsed\/refractory (r\/r) MM to prepare for hematopoietic stem cell transplantation (HSCT). We aimed to determine the myeloablative efficacy of CXCR4 RLT in MM patients and assessed the safety profile of this treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Thirty-eight patients with r\/r MM were treated with 40 cycles of CXCR4-targeting [\n                      <jats:sup>90<\/jats:sup>\n                      Y]Y-PentixaTher or [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PentixaTher. Myeloablative dynamics were closely monitored by examining hematologic parameters before the application of RLT (day 1), on day 2, and on the start day of conditioning chemotherapy (CON, median day 10). Laboratory parameters evaluating organ toxicity were collected and categorized following the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Cairo-Bishop classification was also applied to identify patients experiencing laboratory tumor lysis syndrome (TLS) caused by RLT. After CON, we determined the rate of patients receiving hematopoietic stem cell transplantation (HSCT) followed by successful neutrophile engraftment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Forty cycles of CXCR4-directed RLT were applied. Myeloablative effects resulted in an 81.8% decline in leukocytes and a 69.4% decrease in neutrophil levels till the day of CON (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.0001, respectively), followed by platelets (63.1%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.0001) and hemoglobin (9%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.002). We observed 58 AE Events (1\/58 [1.7%], \u2265 grade 3). CON could be applied successfully after 39\/40 (97.5%) cycles. After CON, in 39\/39 (100%) of the cycles, HSCT was conducted, and successful neutrophil engraftment was reached after 37\/39 (94.9%) of these cycles.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>CXCR4-directed RLT exerted relevant myeloablative effects. When performing HSCT after applying additional CON, successful neutrophile engraftment was reached in the vast majority of the cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005813","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T10:00:08Z","timestamp":1741168808000},"page":"495-500","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple Myeloma"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2921-8452","authenticated-orcid":false,"given":"Niklas","family":"Dreher","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg"},{"name":"Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Lena","family":"D\u00f6rrler","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8954-4220","authenticated-orcid":false,"given":"Sabrina","family":"Kraus","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital W\u00fcrzburg, W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital W\u00fcrzburg, W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9711-7835","authenticated-orcid":false,"given":"Takahiro","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Samnick","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Lapa","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-0819","authenticated-orcid":false,"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital W\u00fcrzburg, W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5740-0537","authenticated-orcid":false,"given":"Sebastian E.","family":"Serfling","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3372-6046","authenticated-orcid":false,"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany"},{"name":"The Russell H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"R1-20250613","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","article-title":"Multiple myeloma: the (r)evolution of current therapy and a glance into future","volume":"105","author":"Gulla","year":"2020","journal-title":"Haematologica"},{"key":"R2-20250613","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41408-023-00900-z","article-title":"Long-term outcomes of allogeneic stem cell transplant in multiple myeloma","volume":"13","author":"Schmidt","year":"2023","journal-title":"Blood Cancer J"},{"key":"R3-20250613","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3390\/cancers15051558","article-title":"Novel agents as main drivers for continued improvement in survival in multiple myeloma","volume":"15","author":"Puertas","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R4-20250613","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.3324\/haematol.2023.282905","article-title":"Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study","volume":"108","author":"McCurdy","year":"2023","journal-title":"Haematologica"},{"key":"R5-20250613","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.exphem.2006.06.017","article-title":"Chemokines in multiple myeloma","volume":"34","author":"Aggarwal","year":"2006","journal-title":"Exp Hematol"},{"key":"R6-20250613","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","article-title":"Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma","volume":"109","author":"Alsayed","year":"2007","journal-title":"Blood"},{"key":"R7-20250613","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1182\/blood-2015-08-665679","article-title":"Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"key":"R8-20250613","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2967\/jnumed.122.265199","article-title":"Theranostics in hematooncology","volume":"64","author":"Buck","year":"2023","journal-title":"J Nucl Med"},{"key":"R9-20250613","first-page":"1687","article-title":"Imaging of C-X-C motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using 68Ga-pentixafor PET","volume":"63","author":"Buck","year":"2022","journal-title":"J Nucl Med"},{"key":"R10-20250613","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.7150\/thno.19050","article-title":"CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"key":"R11-20250613","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2967\/jnumed.122.264207","article-title":"C-X-C motif chemokine receptor 4-targeted radioligand therapy in patients with aAdvanced T-cell lymphoma","volume":"64","author":"Buck","year":"2023","journal-title":"J Nucl Med"},{"key":"R12-20250613","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2967\/jnumed.115.167361","article-title":"First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease","volume":"57","author":"Herrmann","year":"2016","journal-title":"J Nucl Med"},{"key":"R13-20250613","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2967\/jnumed.118.223420","article-title":"Side effects of CXC-chemokine receptor 4-directed endoradiotherapy with pentixather before hematopoietic stem cell transplantation","volume":"60","author":"Maurer","year":"2019","journal-title":"J Nucl Med"},{"key":"R14-20250613","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.hemonc.2017.01.002","article-title":"CXCR4 (CD184) expression on stem cell harvest and CD34(+) cells post-transplant","volume":"10","author":"Asfour","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"R15-20250613","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/RLU.0000000000004974","article-title":"C-X-C motif chemokine receptor 4-targeted radioligand therapy in hematological malignancies-myeloablative effects, antilymphoma activity, and safety profile","volume":"49","author":"Dreher","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R16-20250613","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1182\/blood.V96.13.4096","article-title":"Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program","volume":"96","author":"Davies","year":"2000","journal-title":"Blood"},{"key":"R17-20250613","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJM200101183440303","article-title":"Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers","volume":"344","author":"Bensinger","year":"2001","journal-title":"N Engl J Med"},{"key":"R18-20250613","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Bodei","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R19-20250613","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bjh.13403","article-title":"Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology","volume":"169","author":"Jones","year":"2015","journal-title":"Br J Haematol"},{"key":"R20-20250613","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/cancers14030647","article-title":"Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [(177)Lu]Lu-PSMA I&T","volume":"14","author":"Hartrampf","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R21-20250613","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0272-6386(12)80313-1","article-title":"Modification of Diet in Renal Disease Study Group: design, methods, and results from the feasibility study","volume":"20","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"R23-20250613","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br J Haematol"},{"key":"R24-20250613","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.cell.2022.04.039","article-title":"Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells","volume":"185","author":"Omer-Javed","year":"2022","journal-title":"Cell"},{"key":"R25-20250613","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"key":"R26-20250613","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nbt.3584","article-title":"Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin","volume":"34","author":"Palchaudhuri","year":"2016","journal-title":"Nat Biotechnol"},{"key":"R27-20250613","doi-asserted-by":"crossref","first-page":"351ra105","DOI":"10.1126\/scitranslmed.aae0501","article-title":"Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy","volume":"8","author":"Chhabra","year":"2016","journal-title":"Sci Transl Med"},{"key":"R28-20250613","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1182\/blood-2014-12-617019","article-title":"Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment","volume":"127","author":"Orozco","year":"2016","journal-title":"Blood"},{"key":"R29-20250613","first-page":"57. e51","article-title":"Yttrium-90 anti-CD45 immunotherapy followed by autologous hematopoietic cell transplantation for relapsed or refractory lymphoma","volume":"27","author":"Tuazon","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"R30-20250613","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41409-020-01000-3","article-title":"(90)Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma","volume":"56","author":"Tuazon","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"R31-20250613","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/bmt.2010.280","article-title":"TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions","volume":"46","author":"Hill-Kayser","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"R32-20250613","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7150\/thno.21397","article-title":"Dual targeting of acute leukemia and supporting niche by CXCR4-directed theranostics","volume":"8","author":"Habringer","year":"2018","journal-title":"Theranostics"},{"key":"R33-20250613","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","article-title":"Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors","volume":"55","author":"Styczynski","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"R34-20250613","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/sj.bmt.1705140","article-title":"Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time","volume":"36","author":"Gratwohl","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"R35-20250613","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2004-06-2387","article-title":"Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT","volume":"105","author":"Crawley","year":"2005","journal-title":"Blood"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T08:00:55Z","timestamp":1749801655000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005813","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"2024-11-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}